Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Added a glossary display option. Updated metadata items include Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0, replacing Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T06:17:42.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page shows minor date-related updates to Study Record Dates, with new entries for 2026-01-15 and 2025-12-23 and removal of earlier items like Last Update Posted and 2025-06. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-21T04:43:38.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no substantive changes to the study details are evident.
    Difference
    0.0%
    Check dated 2026-01-14T03:07:33.000Z thumbnail image
  4. Check
    43 days ago
    Change Detected
    Summary
    The page adds a Locations section listing study sites in Georgia, Illinois, Massachusetts, North Carolina, and Pennsylvania, and removes the prior state-location entries; the revision tag updates from v3.3.2 to v3.3.3.
    Difference
    0.6%
    Check dated 2025-12-23T21:50:53.000Z thumbnail image
  5. Check
    71 days ago
    Change Detected
    Summary
    Revision tag updated from v3.2.0 to v3.3.2 on the study page. No substantive changes to study details or eligibility criteria are evident.
    Difference
    0.0%
    Check dated 2025-11-25T11:41:15.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    A government funding status notice has been removed from the page; core study details, eligibility criteria, locations, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T07:12:32.000Z thumbnail image

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.